C/EBPβ enhances immunosuppression activity of myeloid-derived suppressor cells by a P300-mediated acetylation modification

Inflamm Res. 2022 Dec;71(12):1547-1557. doi: 10.1007/s00011-022-01639-2. Epub 2022 Oct 27.

Abstract

Objective: Myeloid-derived suppressor cells (MDSCs) are a major immunosuppressive population in the tumor microenvironment,inhibiting anti-tumor immune response and exerting pro-tumorigenic effect. CCAAT/enhancer-binding protein beta (C/EBPβ), a key transcription factor indispensable for myelopoiesis, plays a fundamental role in regulating expansion and activation of MDSCs. Lysine acetylation can regulate functions of transcription factors. However, the role of C/EBPβ acetylation modification in MDSCs has not been reported.

Materials and methods: MDSCs derived from the spleens of tumor-bearing mice (TB-SP-MDSCs) were isolated by immunomagnetic beads. Bone marrow derived MDSCs were induced by IL-6 and GM-CSF. Western-blot was used to detect the expression of P300 and co-immunoprecipitation (CO-IP) was used to detect the C/EBPβ acetylation in MDSCs. Inhibitor C646 was used to specificly inhibit P300 activity.

Results: In this study, we found that C/EBPβ was acetylated by acetyltransferase P300 in MDSCs. A P300-mediated C/EBPβ acetylation enhanced C/EBPβ transactivation activity on arginase 1 (Arg-1) gene promoter. Inhibition of P300 activity downregulated the inhibitory effects of MDSCs in vitro and attenuated pro-tumorigenic effects of MDSCs in vivo. Additionally, IL-6 from tumor microenvironment could upregulate the expression of P300 and enhance C/EBPβ acetylation in MDSCs.

Conclusion: In general, a P300-mediated C/EBPβ acetylation enhanced C/EBPβ transactivation activity on Arg-1 promoter, thus promoting immunosuppressive function of MDSCs. In view of the critical role of P300 in regulating MDSCs, P300 might be a potential target of anti-tumor immunotherapy.

Keywords: Acetylation; C/EBPβ; Immunosuppression; Myeloid-derived suppressor cells; P300.

MeSH terms

  • Acetylation
  • Animals
  • CCAAT-Enhancer-Binding Protein-beta / genetics
  • CCAAT-Enhancer-Binding Protein-beta / metabolism
  • Immune Tolerance
  • Immunosuppression Therapy
  • Interleukin-6 / metabolism
  • Mice
  • Myeloid-Derived Suppressor Cells*
  • Neoplasms* / pathology
  • Tumor Microenvironment

Substances

  • Interleukin-6
  • CCAAT-Enhancer-Binding Protein-beta